Department of Nephrology, Xiangya Hospital of Central South University, Changsha, China.
Department of Pediatrics, The Third Xiangya Hospital of Central South University, Changsha, China.
Front Immunol. 2023 Mar 21;14:961642. doi: 10.3389/fimmu.2023.961642. eCollection 2023.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the main cause of COVID-19, causing hundreds of millions of confirmed cases and more than 18.2 million deaths worldwide. Acute kidney injury (AKI) is a common complication of COVID-19 that leads to an increase in mortality, especially in intensive care unit (ICU) settings, and chronic kidney disease (CKD) is a high risk factor for COVID-19 and its related mortality. However, the underlying molecular mechanisms among AKI, CKD, and COVID-19 are unclear. Therefore, transcriptome analysis was performed to examine common pathways and molecular biomarkers for AKI, CKD, and COVID-19 in an attempt to understand the association of SARS-CoV-2 infection with AKI and CKD. Three RNA-seq datasets (GSE147507, GSE1563, and GSE66494) from the GEO database were used to detect differentially expressed genes (DEGs) for COVID-19 with AKI and CKD to search for shared pathways and candidate targets. A total of 17 common DEGs were confirmed, and their biological functions and signaling pathways were characterized by enrichment analysis. MAPK signaling, the structural pathway of interleukin 1 (IL-1), and the Toll-like receptor pathway appear to be involved in the occurrence of these diseases. Hub genes identified from the protein-protein interaction (PPI) network, including DUSP6, BHLHE40, RASGRP1, and TAB2, are potential therapeutic targets in COVID-19 with AKI and CKD. Common genes and pathways may play pathogenic roles in these three diseases mainly through the activation of immune inflammation. Networks of transcription factor (TF)-gene, miRNA-gene, and gene-disease interactions from the datasets were also constructed, and key gene regulators influencing the progression of these three diseases were further identified among the DEGs. Moreover, new drug targets were predicted based on these common DEGs, and molecular docking and molecular dynamics (MD) simulations were performed. Finally, a diagnostic model of COVID-19 was established based on these common DEGs. Taken together, the molecular and signaling pathways identified in this study may be related to the mechanisms by which SARS-CoV-2 infection affects renal function. These findings are significant for the effective treatment of COVID-19 in patients with kidney diseases.
严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)是导致 COVID-19 的主要原因,在全球范围内导致数亿例确诊病例和超过 1820 万人死亡。急性肾损伤(AKI)是 COVID-19 的常见并发症,导致死亡率增加,特别是在重症监护病房(ICU)环境中,慢性肾脏病(CKD)是 COVID-19 及其相关死亡率的高风险因素。然而,AKI、CKD 和 COVID-19 之间的潜在分子机制尚不清楚。因此,进行了转录组分析,以检查 AKI、CKD 和 COVID-19 的常见途径和分子生物标志物,试图了解 SARS-CoV-2 感染与 AKI 和 CKD 的关联。使用来自 GEO 数据库的三个 RNA-seq 数据集(GSE147507、GSE1563 和 GSE66494)检测 COVID-19 合并 AKI 和 CKD 的差异表达基因(DEGs),以寻找共享途径和候选靶标。共确定了 17 个共同的 DEG,并通过富集分析对其生物学功能和信号通路进行了表征。MAPK 信号、白细胞介素 1(IL-1)的结构途径和 Toll 样受体途径似乎与这些疾病的发生有关。从蛋白质-蛋白质相互作用(PPI)网络中鉴定的枢纽基因,包括 DUSP6、BHLHE40、RASGRP1 和 TAB2,是 COVID-19 合并 AKI 和 CKD 的潜在治疗靶点。共同的基因和途径可能主要通过免疫炎症的激活在这三种疾病中发挥致病作用。还构建了数据集的转录因子(TF)-基因、miRNA-基因和基因-疾病相互作用网络,并在 DEG 中进一步确定了影响这三种疾病进展的关键基因调节剂。此外,还基于这些共同的 DEG 预测了新的药物靶点,并进行了分子对接和分子动力学(MD)模拟。最后,基于这些共同的 DEG 建立了 COVID-19 的诊断模型。总之,本研究中鉴定的分子和信号通路可能与 SARS-CoV-2 感染影响肾功能的机制有关。这些发现对于有效治疗患有肾脏疾病的 COVID-19 患者具有重要意义。